2,533
Participants
Start Date
April 17, 2017
Primary Completion Date
June 30, 2020
Study Completion Date
December 31, 2020
Auckland City Hospital, Grafton
Royal Prince Alfred Hospital, Camperdown
Royal Adelaide Hospital, Adelaide
Chulabhorn Hospital, Bang Khen
National Cancer Institute, Ratchathewi
Siriraj Hospital, Mahidol University, Bangkok Noi
St Vincent Hospital, Catholic University Medical College, Gyeonggi-do
Ajou University Hospital, Gyeonggi-do
China Medical University Hospital, Taichung
Beijing Cancer Hospital, Beijing
National University Hospital, Singapore
Singapore General Hospital, Singapore
National Cancer Centre, Singapore
Zhongshan Hospital, Shanghai
Nanjing Bayi Hospital, Nanjing
Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
Southwest Hospital of Third Military Medical University, Chongqing
Guangxi Medical University Cancer Center, Nanning
Flinders Medical Centre, Bedford Park
Queen Mary Hospital, Hong Kong
University of Tokyo, Tokyo
Seoul National University Bundang Hospital, Gyeonggi-do
Korea University Anam Hospital, Seoul
Samsung Medical Center, Seoul
Severance Hospital, Yonsei University College of Medicine, Seoul
National Cheng Kung University Hospital, Tainan City
Chang Gung Memorial Hospital-KS, Taipei
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Kinki University School of Medicine, Ōsakasayama
National Cancer Centre, Japan, Chūōku
Kyorin University School of Medicine, Mitaka-shi
Asan Medical Centre, Seoul
St. Mary's Hospital, Seoul
Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group
UNKNOWN
Singapore Clinical Research Institute
OTHER
Iqvia Pty Ltd
INDUSTRY
National Cancer Centre, Singapore
OTHER